Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma

Advances in Experimental Medicine and Biology

Volumn 804, Issue , 2014, Pages

  Jaffe, Norman ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Current status; Limb salvage; Neoadjuvant therapy; Osteosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DNA; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; IMMUNOSTIMULATING AGENT; INTERFERON; LANATOSIDE C; MELPHALAN; MESNA; METHOTREXATE; MIFAMURTIDE; MITOMYCIN; OXAZAPHOSPHORINE DERIVATIVE; RAZOXANE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; DISEASE FREE SURVIVAL; DNA SYNTHESIS INHIBITION; DRUG BINDING SITE; DRUG STRUCTURE; ELECTROLYTE DISTURBANCE; HEMORRHAGIC CYSTITIS; HUMAN; KIDNEY DYSFUNCTION; LIMB SALVAGE; LIVER DYSFUNCTION; LUNG METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MUCOSA INFLAMMATION; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROLOGIC DISEASE; OSTEOSARCOMA; OTOTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STRUCTURE ANALYSIS; SURVIVAL RATE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; ADJUVANT CHEMOTHERAPY; BONE TUMOR; DRUG ADMINISTRATION; DRUG ADMINISTRATION ROUTE; HISTORY; LUNG TUMOR; METASTASIS; PATHOLOGY; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; METHOTREXATE; OSTEOSARCOMA; TREATMENT OUTCOME;

EID: 84907180146     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-04843-7_1     Document Type: Article

References (126)

1. Gross SW (1879) Sarcomas of the long bones: based on a study of one hundred and sixty five cases. Am J Med Sci 8: 338-377.
2. Jaffe N, Frei E III, Traggis D et al (1974) Adjuvant methotrexate and citrovorin factor in osteogenic sarcoma. N Engl J Med 291: 994-997.
3. Jeffree GM, Price CH, Sissons HA (1975) The metastatic patterns of osteosarcoma. Br M Cancer 32(1): 87-107.
4. Friedman M, Carter SK (1972) The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol 4(5): 482-510.
5. Sullivan MP, Sutow WW, Taylor G (1963) L-phenylalanine mustard as treatment for metastatic osteogenic sarcoma in children. J Ped 63: 227-237.
6. Sutow WW, Sullivan MP, Fernbach DJ et al (1975) Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. Cancer 36: 1598-1602.
7. Evans AE (1961) Mitomycin C. Cancer Chemother Rep 14: 1-9.
8. Frank W, Osterberg A (1971) Mitomycin C (NSC-26980) clinical brochure. Cancer Chemother Rep 55: 285-291.
9. Finkelstein JZ, Hittle RE, Hammond CD (1969) Evaluation of a high dose cyclophosphamide regimen in childhood tumors. Cancer 23: 1239-1242.
10. Haggard M (1967) Cyclophosphamide (NSC-26271) in the treatment of children with malignant neoplasms. Cancer Chemother Rep 51: 403-405.
11. Pinkle D (1962) Cyclophosphamide in children with cancer. Cancer 15: 42-49.
12. Sutow WW, Vietti TJ, Fernbach DJ et al (1971) Evaluation of chemotherapy in children with metastatic Ewing's sarcoma and osteogenic sarcoma. Cancer Chemother Rep 55: 67-81.
13. Selawry O, Holland J, Wolman J (1988) Effect of vincristine (NSC-67574) on malignant solid tumors in children. Cancer Chemother Rep 52: 497-560.
14. Groesbeck H, Budmore J (1963) Evaluation of 5-fluouracil (5-FU) in surgical practice. Am Surg 29: 683-691.
15. Jaffe N, Traggis D, Enriquez C (1971) Evaluation of mitomycin C (NSC-26980), phenylalanine mustard (NSC-16210) and vincristine (NSC-67574) in the treatment of osteogenic sarcoma. Cancer Chemother Rep 55: 181-191.
16. Sutow WW (1975) Combination chemotherapy with Adriamycin (NSC-123127) in primary treatment of osteosarcoma (Part III). Cancer Chemother Rep 6: 315-317.
17. Sutow WW, Gehan EA, Dyment PC et al (1978) Multi-drug adjuvant chemotherapy in osteosarcoma: interim report of the Southwest Oncology Group Studies. Cancer Treat Rep 62(2): 265-269.
18. Wilbur J (1974) Combination chemotherapy for rhabdomyosarcoma. Cancer Chemother Rep 58(2): 281-284.
19. Herson J, Sutow WW, Elder K (1980) Adjuvant chemotherapy in non-metastatic osteosarcoma: a Southwest Oncology Group Study. Med Pediatr Oncol 8: 343-352.
20. Cortez EP, Holland JF, Wang JJ et al (1972) Doxorubicin in disseminated osteosarcoma. JAMA 221: 1132-1137.
21. Bonnaonna G, Monifardi S, Douglass RC et al (1970) Phase I and preliminary phase II evaluation of Adriamycin (NSC-123127). Cancer Res 30: 2572-2582.
22. Cortez EP, Holland JF, Wang JJ et al (1972) Chemotherapy of adjuvant osteosarcoma. In: Proceedings of the 24th Symposium of the Colston Research Society, April, 1972. Butterworths, London.
23. Gottlieb JA, Baker LH, O'Bryan RM et al (1975) Adriamycin (NSC-123127) used alone and in combination with soft tissue bone sarcoma. Cancer Chemother Rep 3: 271-282.
24. Middleman E, Luce L, Frei E (1971) Clinical trials with Adriamycin. Cancer 28: 844-850.
25. O'Bryan RM, Luce JK, Talley R et al (1973) Phase II evaluation of Adriamycin in human neoplasia. Cancer 32: 1-7.
26. Cortez EP, Holland JF, Wang JJ et al (1974) Amputation and Adriamycin in primary osteosarcoma. N Engl J Med 291: 998-1000.
27. Cassady JR, Richter MP, Piro AJ et al (1975) Radiation Adriamycin interactions-preliminary clinical observations. Cancer 36: 946-949.
28. Eilber FR, Grant T, Morton DC (1978) Adjuvant chemotherapy for osteosarcoma. Cancer Treat Rep 62: 213-216.
29. Seifert CF, Nesser ME, Thompson DF (1994) Dexrazoxane in the prevention of doxorubicininduced cardiotoxicity. Ann Pharmacother 28: 1063-1072.
30. Smith MA, Ungerleider RS, Horowitz ME et al (1991) Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Nat Cancer Inst 83: 1460-1470.
31. Farber S, Diamond LK, Mercer RD et al (1946) Temporary remissions in children in acute leukemia produced by folic acid antagonist 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 238: 787-793.
32. Fyfe MJ, Goldman ID (1973) Characteristics of the vincristine augmentation of methotrexate uptake in Ehrlich ascites tumor cells. J Biol Chem 248: 5067-5073.
33. Goldin A, Mantel N, Greenhouse SW et al (1954) Effect of delayed administration of citrovorum factor on the antileukemic effectiveness of aminopterin in mice. Cancer Res 14: 43-48.
34. Djerassi I, Abir E, Boyer GL et al (1966) Long-term remissions in childhood acute leukemia: use of infrequent infusions of methotrexate; supportive roles of platelet transfusions and citrovorum factor. Clin Pediatr 5: 502-509.
35. Jaffe N (1972) Recent advances in the chemotherapy of osteogenic sarcoma. Cancer 30: 1627-1631.
36. Skipper HE, Schabel FM, Wilcox WS (1964) Experimental evaluation of potential anticancer agents. XIV Further study of certain basic concepts underlying chemotherapy of leukemia. Cancer Chemother Rep 35: 1-28.
37. Laster WR Jr, Mayo JG, Simpson-Herrin L et al (1969) Success and failure in the treatment of solid tumors. II. Kinetic parameters and "cell cure" of moderately advanced carcinoma. Cancer Chemother Rep 53: 169-188.
38. Schabel FM Jr (1975) Concepts for systemic treatment of micro-metastases. Cancer 35: 15-24.
39. Jaffe N (1974) Progress report on high-dose methotrexate (NSC-740) with citrovorum rescue in the treatment of metastatic bone tumor. Cancer Chemother Rep 58: 275-280.
40. Jaffe N, Traggis D (1975) Toxicity of high-dose methotrexate (NSC-740) and citrovorum factor (NSC-3590) in osteogenic sarcoma. Cancer Chemother Rep 6: 31-36.
41. Jaffe N, Traggis D, Cassady JR et al (1976) Multidisciplinary treatment for macrometastatic osteogenic sarcoma. Br Med J 2: 1039-1041.
42. Frei E III, Jaffe N, Tattersall MHN, Pitman S, Parker L (1975) New approaches to cancer chemotherapy with methotrexate. N Engl J Med 292: 846-851.
43. Pratt C, Shanks E, Hustu O et al (1977) Adjuvant multiple drug chemotherapy for osteosarcoma of the extremity. Cancer 39: 51-57.
44. Rosen G, Tefft M, Martinez A et al (1975) Combination chemotherapy and radiation therapy in the treatment of metastatic osteosarcoma. Cancer 35: 622-630.
45. Muggia FM, Louis AC (1978) Five years of adjuvant chemotherapy: more questions than answers. Cancer Treat Rep 62: 30-36.
46. Taylor WF, Ivins JC, Prichard DJ et al (1985) Trends and variability in survival among patients with osteosarcoma: a 7-year update. Mayo Clin Proc 60(2): 91-104.
47. Edmonson JH, Green SJ, Ivins JC et al (1984) A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol 2: 152-156.
48. Carter SK (1984) Adjuvant chemotherapy in osteogenic sarcoma: the triumph that isn't? J Clin Oncol 2: 147-148.
49. Gehan EA, Sutow WW, Urube Botero T et al (1978) Osteosarcoma. The MD Anderson Experience 1850-1974. In: Terry WD, Windhorst D (eds) Immunotherapy of cancer. Present status of trials in man. Raven, New York, NY, pp 271-282.
50. Mike V, Marcove RC (1978) Osteogenic sarcoma under the age of 21. Experiences at Memorial Sloan Kettering Cancer Center. In: Terry WD, Windhorst D (eds) Immunotherapy of cancer. Present status of trials in man. Raven, New York, NY, pp 283-292.
51. Frei E III, Blum R, Jaffe N (1978) Sarcoma: natural history and treatment. In: Terry WD, Windhorst D (eds) Immunotherapy of cancer. Present status of trials in man. Raven, New York, NY, pp 248-255.
52. Campanacci M, Bacci G, Bertoni F et al (1981) The treatment of osteosarcoma of the extremities: twenty years' experience at the Instituto Ortopedico Rizzoli. Cancer 48: 1569-1581.
53. Link MP, Vietti TJ (1983) Role of adjuvant chemotherapy in the treatment of osteosarcoma. Cancer Treat Rep 67: 744-745.
54. Lang EB, Levin AS (1982) Is it ethical not to conduct a prospectively controlled trial of adjuvant chemotherapy in osteosarcoma? Cancer Treat Rep 66: 1699-1704.
55. Link MP, Goorin AM, Miser A et al (1986) The effect of adjuvant chemotherapy on relapsefree survival in patients with osteosarcoma of the extremity. N Engl J Med 314: 1600-1606.
56. Eilber FR, Douglass HI Jr, Mendel ER et al (1986) Adjuvant Adriamycin and cisplatin in newly diagnosed nonmetastatic osteosarcoma of the extremity. J Clin Oncol 4: 353-362.
57. Jaffe N (1986) Osteosarcoma. N Engl J Med 314: 1513.
58. Holland JF (1987) Adjuvant chemotherapy of osteosarcoma: no runs, no hits, two men left on base. J Clin Oncol 5: 4-6.
59. Jaffe N, Gorlick R (2008) High-dose methotrexate in osteosarcoma: let the questions surcease-time for final acceptance. J Clin Oncol 24: 4365-4366.
60. Van Dalen EC, van As JW, de Camargo B Methotrexate for high-grade osteosarcoma in children and young adults. Cochrane Database of Systematic Reviews 2011, Issue 5. Art. No.: CD006325. doi: 10. 1002/14651858. CD006325. pub3.
61. Jaffe N, Robertson R, Ayala A, Wallace S (1985) Comparison of intra-arterial CDP II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J Clin Oncol 3: 1101-1104.
62. Jaffe N (1979) Antifolate rescue use of high-dose methotrexate and citrovorin factor. In: Rossowsky A (ed) Advances in chemotherapy. Marcel Decker Inc., New York, NY, pp 111-141.
63. Rosenberg B, Van Camp L, Krigas T (1965) Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205(4972): 698-699.
64. Baum E, Greenberg L, Gaynon P et al (1978) Use of cis-diamminedichloroplatinum-II (CDDP) in osteogenic sarcoma in children (Abstract C-315). Proc AACR-ASCO 19: 385.
65. Nitschke R, Starling KA, Vats T et al (1978) Cis-diamminedichloroplatinum II (NSC119875) In: Childhood malignancies. A Southwest Oncology Group study. Med Pediatr Oncol 4: 127-132.
66. Ochs JJ, Freeman AI, Douglass HO Jr et al (1978) Cis-diamminedichloroplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 62: 239-245.
67. Pratt CB, Champion JE, Senzer N et al (1985) Treatment of unresectable or metastatic osteosarcoma with cisplatin or cisplatin-doxorubicin. Cancer 56: 1930-1933.
68. Jaffe N, Knapp J, Chuang VP et al (1983) Osteosarcoma intra-arterial treatment of the primary tumor with cis-diamminedichloroplatinum-II (CDP). Angiographic, pathologic and pharmacologic studies. Cancer 51: 402-407.
69. Jaffe N, Raymond AK, Ayala A et al (1989) Effect of cumulative courses of intra-arterial cis-diamminedichloroplatinum II on the primary tumor in osteosarcoma. Cancer 63: 63-68.
70. Jaffe N (2009) Osteosarcoma: review of the past, impact on the future. The American experience. In: Jaffe N, Bruland O, Bielack S (eds) Pediatric and adolescent osteosarcoma. Springer, New York, NY, pp 239-262.
71. Hudson M, Jaffe MR, Jaffe N et al (1990) Pediatric osteosarcoma: therapeutic strategies, results and prognostic factors derived from a 10-year experience. J Clin Oncol 8: 1988-1997.
72. Lin PP, Patel S (2013) Osteosarcoma. In: Lin PP, Patel S (eds) Bone sarcoma. Springer, New York, NY, pp 75-97.
73. Petrilli AS, de Camargo B, Filho VO et al (2006) Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol 24: 1161-1168.
74. Goodman LS, Wintrobe MM, Dameshek W et al (1946) Nitrogen mustard therapy. JAMA 132(3): 126-132.
75. Sutow WW, Sullivan MP, Wilbur JR et al (1975) The study of adjuvant chemotherapy in osteogenic sarcoma. J Clin Pharmacol 15: 530-533.
76. Antman KH, Montella D, Rosenbaum C et al (1985) Phase II trial of ifosfamide with mesna in previously treated metastatic osteosarcoma. Cancer Treat Rep 69: 499-504.
77. Bowman LG, Mayer WN, Douglass EC et al (1987) Activation of ifosfamide in metastatic and unresectable osteosarcoma (Abstract). Proc ASCO C-214: 844.
78. Meyer WH, Pratt CB, Farham D et al (1988) The activity of ifosfamide (IFOS) in previously pretreated patients with osteosarcoma (OS): preliminary results of SJCRH OS-86 Study. Proc ASCO 7: 26180.
79. Goorin AM, Harris MB, Bernstein M et al (2002) Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a Pediatric Oncology Group Trial. J Clin Oncol 20: 426-433.
80. Kleinerman ES, Jia S-F, Griffin J (1992) Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Onc 10(8): 1310-1316.
81. Meyers P, Schwartz CL, Krailo M et al (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 26: 633-688.
82. Navid F, Willert JR, McCarville MB et al (2008) Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 113: 419-425.
83. Fox E, Aplenc R, Bagatell R (2010) A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor in children and adolescents with refractory solid tumors. J Clin Oncol 28: 5174-5181.
84. Andrews NA (2013) Osteosarcoma therapy: what is the way forward? IBMS BoneKEy, doi 1038/bonekey. 2013. 106.
85. Arndt CAS, Koshkina NV, Inwards CY (2010) Inhaled granulocyte macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma on disease-free survival and immunomodulation. A report from the Children's Oncology Group. Cancer Clin Res 16: 4024-4030.
86. Chou AJ, Gupta R, Bell MD et al (2013) Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed progressive osteosarcoma metastatic to the lung. Ped Blood Can 60(4): 580-586.
87. Rosen G, Caparros B, Huvos AG et al (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49: 1221-1230.
88. Huvos AG, Rosen G, Marcove RC (1997) Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 101: 14-18.
89. DeVita VT (1983) The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer. Cancer 51: 1209-1220.
90. Goldie JH, Coleman AJ (1979) A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727-1733.
91. Murray JA, Jessup K, Romsdahl M et al (1985) Limb salvage surgery in osteosarcoma: early experience at MD Anderson Hospital and Tumor Institute. Cancer Treat Symp 3: 131-137.
92. Picci P, Bacci G, Campanna R et al (1988) Neoadjuvant chemotherapy for osteosarcoma-results of a prospective study. In: Ryan JR, Baker LO (eds) Recent concepts in sarcoma treatment. Kluver Academic Publishers, Dordrecht, pp 291-295.
93. Picci P, Bacci G, Neff JR (1990) The influence of preoperative chemotherapy (POC) in the surgical planning in patients (PTS) with osteosarcoma (OS): a histopathological study on 205 PTS. Proc ASCO 9: 310.
94. Jaffe N, Spears R, Eftekhari F et al (1987) Pathologic fracture in osteosarcoma: effect of chemotherapy in primary tumor and survival. Cancer 59: 701-709.
95. Schabel FM Jr (1969) The use of tumor growth kinetics in planning "curative" chemotherapy of advanced solid tumors. Cancer Res 29: 2384-2389.
96. Schabel FM (1977) Rationale for adjuvant chemotherapy. Cancer 39: 2875-2882.
97. Nachman J, Simon MA, Dean L et al (1987) Disparate histologic prognosis in simultaneously resected primary and metastatic osteosarcoma following intravenous neoadjuvant chemotherapy. J Clin Oncol 5: 1185-1190.
98. Meyers PA, Heller G, Healy J et al (1992) Chemotherapy for non metastatic osteogenic sarcoma. The Memorial Sloan Kettering Experience. J Clin Oncol 10: 5-13.
99. Winkler K, Beron G, Dellin G et al (1988) Neoadjuvant chemotherapy for osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6: 329-337.
100. Goorin AM, Schwartzentruber DJ, Devidas M et al (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for non metastatic osteosarcoma. Pediatric Oncology Group Study POG-8651. J Clin Oncol 21: 1574-1580.
101. Proviser AJ, Ettinger LJ, Nachman JB et al (1997) Treatment of non metastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 15(1): 1076-1084.
102. Smeland B, Muller C, Alvegard TA et al (2003) Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 30(4): 488-494.
103. Benjamin RS, Chawala SP, Murray J et al (1984) Preoperative chemotherapy for osteosarcoma: a treatment approach facilitating limb salvage with major prognostic indications. In: Jones SF, Salmon SE (eds) Adjuvant therapy of cancer IV. Grune and Stratton, Philadelphia, PA, pp 601-610.
104. Marina N, Bielack S, Whelan S et al (2009) International collaboration is feasible in trials for rare conditions: the EURAMOS experience. In: Jaffe N, Bruland O, Bielack S (eds) Pediatric and adolescent osteosarcoma. Springer, New York, NY, pp 339-353.
105. Bielack SS, Smeland S, Whelan J et al (2013) MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-"good response" randomization. J Clin Oncol 31 (suppl; abstr LBA10504).
106. Briccoli A, Rocca M, Salone M et al (2005) Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer 104(8): 1721-1725.
107. Martini N, McCormack PM (1988) Pulmonary resection in sarcoma metastases. In: Ryan JR, Baker LO (eds) Recent concepts in sarcoma treatment. Kluwer Academic Publishers, Dordrecht, pp 197-200.
108. Jaffe N, Smith E, Abelson HT et al (1983) Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy. J Clin Oncol 1: 252-254.
109. Harting MT, Blakely ML, Jaffe N et al (2006) Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg 41(1): 194-199.
110. Phemister DB (1940) Conservative surgery in the treatment of bone tumors. Surg Gynecol Obstet 70: 355-364.
111. Parrish FF (1968) Treatment of bone tumors by total excision and replacement with massive autologous and homologous grafts. J Bone Joint Surg 48A: 968-990.
112. Jaffe N, Carrasco H, Raymond K et al (2002) Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer 95: 2202-2210.
113. McCarten KM, Jaffe N, Kirkpatrick JA (1980) The changing radiographic appearance of osteosarcoma. Ann Radiol 23: 203-208.
114. Bielack S, Jurgens H, Jundt G et al (2009) Osteosarcoma: the COSS experience. In: Jaffe N, Bruland O, Bielack S (eds) Pediatric and adolescent osteosarcoma. Springer, New York, NY, pp 289-308.
115. Myers PA, Gorlick R, Heller G et al (1998) Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan Kettering (T12) protocol. J Clin Oncol 16(7): 2452-2458.
116. Ferrari S, Palmerini E, Staals EL et al (2009) The treatment of nonmetastatic high-grade osteosarcoma of the extremity: review of the Italian Rizzoli experience. Impact on the future experience. In: Jaffe N, Bruland O, Bielack S (eds) Pediatric and adolescent osteosarcoma. Springer, New York, NY, pp 275-287.
117. Bruland OS, Bauer H, Alvegard T et al (2009) Treatment of osteosarcoma. The Scandinavia Sarcoma Group experience. In: Jaffe N, Bruland O, Bielack S (eds) Pediatric and adolescent osteosarcoma. Springer, New York, NY, pp 309-318.
118. Delepine N, Delepine G, Jasmine C et al (1988) Importance of age and methotrexate dosage: prognosis in children and young adults with high-grade osteosarcoma. Biomed Pharmacother 42: 257-262.
119. Le Deley M-C, Guinebretiere J-M, Gentet J-C (2007) A randomized trial comparing preoperative high-methotrexate plus doxorubicin to high dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 43(4): 751-761.
120. Pratt CB, Luo X, Fay L et al (1996) Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide. A single hospital experience. Med Pediatr Oncol 27: 145-148.
121. Daw NE, Neel MD, Rao BN (2011) Frontline treatment of localized osteosarcoma without methotrexate: results of the St Jude Children's Research Hospital OS99 trial. Cancer 117(12): 2770-2778.
122. Meyer WH, Pratt CB, Poquette CA et al (2001) Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol 19: 171-182.
123. Krailo M, Ertel I, Makley J et al (1987) A randomized study comparing high dose methotrexate with moderate dose methotrexate as components of adjuvant therapy in childhood nonmetastatic osteosarcoma: a report from the Children's Cancer Study Group. Med Pediatr Oncol 15: 69-77.
124. Ayan I, Kebudi R, Ozger H (2009) Childhood osteosarcoma: multimodal therapy in a singleinstitution Turkish series. In: Jaffe N, Bruland O, Bielack S (eds) Pediatric and adolescent osteosarcoma. Springer, New York, NY, pp 319-338.
125. Bernthal N, Federman N, Nelson S (2012) Early pathologic response to neoadjuvant therapy predictive of long term (>25 year) survival in osteosarcoma. Paper presented at 2012 annual meeting of the Connective Tissue Oncology Society, Prague, Czech Republic, and 14-17 November 2012.
126. Craft AW (2009) Osteosarcoma: the European Osteosarcoma Intergroup (EOI) perspective. In: Jaffe N, Rutland O, Bielack S (eds) Pediatric and adolescent osteosarcoma. Springer, New York, NY, pp 263-274.